{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T20:18:02Z","timestamp":1785269882957,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jpba.2024.116531","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T05:16:30Z","timestamp":1729142190000},"page":"116531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Assay for the quantification of abemaciclib, its metabolites, and olaparib in human plasma by liquid chromatography-tandem mass spectrometry"],"prefix":"10.1016","volume":"253","author":[{"given":"Kasey L.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole L.","family":"Abbott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo Young","family":"Na","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Q.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitch A.","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116531_bib1","author":"Food","year":"2018","journal-title":"Guid. Ind.: Bioanal. Method Valid."},{"key":"10.1016\/j.jpba.2024.116531_bib2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40265-015-0345-6","article-title":"Olaparib: first global approval","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116531_bib3","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2024.116531_bib4","unstructured":"AstraZeneca Pharmaceuticals, LYNPARZA\u00ae (olaparib) tablets, for oral use, (2023). \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/208558s028lbl.pdf\u3009 (Accessed 15 September 2024)."},{"key":"10.1016\/j.jpba.2024.116531_bib5","unstructured":"Small Molecules in Oncology by Uwe M. Martens (Ebook) - Read free for 30 days, n.d. \u3008https:\/\/www.everand.com\/book\/576592942\/Small-Molecules-in-Oncology\u3009 (Accessed 2 February 2024)."},{"key":"10.1016\/j.jpba.2024.116531_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.4155\/bio-2021-0039","article-title":"Quantification of abemaciclib and metabolites: evolution of bioanalytical methods supporting a novel oncolytic agent","volume":"13","author":"Wickremsinhe","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpba.2024.116531_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1158\/2159-8290.CD-16-0095","article-title":"Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors","volume":"6","author":"Patnaik","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.jpba.2024.116531_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","article-title":"Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine","volume":"32","author":"Gelbert","year":"2014","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.jpba.2024.116531_bib9","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1158\/1078-0432.CCR-13-2846","article-title":"Semi-mechanistic pharmacokinetic\/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4\/6 inhibitor, in mice bearing human tumor xenografts","volume":"20","author":"Tate","year":"2014","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jpba.2024.116531_bib10","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1124\/dmd.114.062745","article-title":"Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft","volume":"43","author":"Raub","year":"2015","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"10.1016\/j.jpba.2024.116531_bib11","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-17-0754","article-title":"MONARCH 1, a phase II study of Abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+\/HER2- metastatic breast cancer","volume":"23","author":"Dickler","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jpba.2024.116531_bib12","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1158\/1078-0432.CCR-17-3575","article-title":"Abemaciclib, a selective CDK4\/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer In Vitro and In Vivo","volume":"24","author":"Naz","year":"2018","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.jpba.2024.116531_bib13","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.jpba.2024.116531_bib14","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/jco.2013.31.15_suppl.2500","article-title":"A first-in-human phase I study of the CDK4\/6 inhibitor, LY2835219, for patients with advanced cancer","volume":"31","author":"Shapiro","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2024.116531_bib15","article-title":"S. N, Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib","volume":"59","author":"Sl","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.jpba.2024.116531_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00280-023-04591-y","article-title":"Bidirectional pharmacokinetic drug interactions between olaparib and metformin","volume":"93","author":"Stanis\u0142awiak-Rudowicz","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116531_bib17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jchromb.2013.09.020","article-title":"Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma","volume":"940","author":"Nijenhuis","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2024.116531_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/FTD.0000000000000497","article-title":"Development and validation of a simultaneous quantification method of ruxolitinib, vismodegib, olaparib, and pazopanib in human plasma using liquid chromatography coupled with tandem mass spectrometry","volume":"40","author":"Pressiat","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116531_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121844","article-title":"A simple and fast LC-MS\/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma","volume":"1132","author":"Jolibois","year":"2019","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2024.116531_bib20","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1007\/s00216-019-01932-w","article-title":"Development and validation of a bioanalytical method for the quantification of the CDK4\/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry","volume":"411","author":"Mart\u00ednez-Ch\u00e1vez","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116531_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2019.121925","article-title":"Development and validation of an integrated LC-MS\/MS assay for therapeutic drug monitoring of five PARP-inhibitors","volume":"1138","author":"Bruin","year":"2020","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2024.116531_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.114225","article-title":"Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC-MS\/MS","volume":"203","author":"Mart\u00ednez-Ch\u00e1vez","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116531_bib23","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jchromb.2011.05.003","article-title":"Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma","volume":"879","author":"Sparidans","year":"2011","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.jpba.2024.116531_bib24","doi-asserted-by":"crossref","first-page":"7672","DOI":"10.3390\/curroncol30080556","article-title":"Clinical considerations for the integration of adjuvant olaparib into practice for early breast cancer: a canadian perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.jpba.2024.116531_bib25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/psp4.12544","article-title":"Development and application of a mechanistic population modeling approach to describe abemaciclib pharmacokinetics","volume":"9","author":"Chigutsa","year":"2020","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116531_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00280-016-3085-8","article-title":"Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer","volume":"78","author":"Fujiwara","year":"2016","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116531_bib27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11523-020-00789-9","article-title":"A randomized phase i study of abemaciclib in chinese patients with advanced and\/or metastatic cancers","volume":"16","author":"Zhang","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.jpba.2024.116531_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cpt.1103","article-title":"Physiologically based pharmacokinetic modeling for olaparib dosing recommendations: bridging formulations, drug interactions, and patient populations","volume":"105","author":"Pilla Reddy","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116531_bib29","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00280-019-03799-1","article-title":"Pharmacokinetics and safety of olaparib tablets as monotherapy and in combination with paclitaxel: results of a Phase I study in Chinese patients with advanced solid tumours","volume":"83","author":"Yuan","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116531_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00280-016-3106-7","article-title":"Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours","volume":"78","author":"Yonemori","year":"2016","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524005739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T07:18:33Z","timestamp":1733037513000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524005739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"alternative-id":["S0731708524005739"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116531","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assay for the quantification of abemaciclib, its metabolites, and olaparib in human plasma by liquid chromatography-tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116531"}}